Search

Your search keyword '"Mariampillai, Kuberaka"' showing total 34 results

Search Constraints

Start Over You searched for: Author "Mariampillai, Kuberaka" Remove constraint Author: "Mariampillai, Kuberaka"
34 results on '"Mariampillai, Kuberaka"'

Search Results

1. Sirolimus for treatment of patients with inclusion body myositis: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2b trial

3. Inclusion-body myositis associated with Sjögren’s disease: clinical characteristics and comparison with other Sjögren-associated myositis

4. Granulomatosis-associated myositis: High prevalence of sporadic inclusion body myositis

5. In inflammatory myopathies, dropped head/bent spine syndrome is associated with scleromyositis: an international case–control study

6. Innate and Adaptive Immune Response in Fabry Disease

7. Granulomatosis-associated myositis: High prevalence of sporadic inclusion body myositis

9. Necrosis in anti-SRP+ and anti-HMGCR+myopathies: Role of autoantibodies and complement

10. Anti-PM-Scl antibodies–positive patients encompass three different groups with distinct prognoses

11. Pulmonary arterial hypertension in idiopathic inflammatory myopathies: Data from the French pulmonary hypertension registry and review of the literature

12. Anti-PM-Scl antibodies–positive patients encompass three different groups with distinct prognoses.

13. Occurrence of focal myositis during Behçet's disease: The identification of a specific vasculitis-associated focal myopathy.

15. Systematic retrospective study of 64 patients with anti-Mi2 dermatomyositis: A classic skin rash with a necrotizing myositis and high risk of malignancy

19. Anti-RNP antibodies delineate a subgroup of necrotizing myositis

20. Rituximab and Cyclophosphamide in Antisynthetase Syndrome–related Interstitial Lung Disease: An Observational Retrospective Study

21. Ultrasensitive Interferons quantification in idiopathic inflammatory myopathies serve as biomarkers of activity in dermatomyositis and anti-synthetase syndrome

22. Moving from Dermatomyositis Associated with Anti-Melanoma Differentiation-Associated Gene 5 Antibody to Anti-Melanoma Differentiation-Associated Gene 5 Syndrome

23. Moving from Dermatomyositis Associated with Anti-MelanomaDifferentiation-Associated Gene 5 Antibody to Anti-MelanomaDifferentiation-Associated Gene 5 Syndrome

24. Granulomatosis-associated myositis

25. Necrosis in anti-SRP + and anti-HMGCR + myopathies

26. Rapamycin vs. Placebo for the Treatment of Inclusion Body Myositis: improvement of the 6 min walking distance, a functional scale, the FVC and muscle quantitative MRI

29. Long-term exposure to Myozyme results in a decrease of anti-drug antibodies in late-onset Pompe disease patients

30. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody

31. Efficacy of Rituximab in Refractory Inflammatory Myopathies Associated with Anti- Synthetase Auto-Antibodies: An Open-Label, Phase II Trial

32. Necrosis in anti-SRP+ and anti-HMGCR+myopathies: Role of autoantibodies and complement.

33. Ultrasensitive interferons quantification reveals different cytokine profile secretion in inflammatory myopathies and can serve as biomarkers of activity in dermatomyositis.

34. Necrosis in anti-SRP + and anti-HMGCR + myopathies: Role of autoantibodies and complement.

Catalog

Books, media, physical & digital resources